Also known as Natalizumab, Tysabri is used in the treatment of the relapsing-remitting form of multiple sclerosis (MS). This medicine may extend the time between relapses.
Be sure to tell your doctor of any allergies you have whether it is to medication or food, preservatives, or dyes. Tell your doctor immediately if you are, or become pregnant, or are breastfeeding, as it is unknown how Tysabri may affect your baby. Also, tell your doctor of any other medications you are taking, including vitamins and supplements, and any medical conditions you may have.
It is very important that you take this medicine exactly as your doctor tells you to. Do not take more or less medicine than directed, and never stop taking Tysabri without discussing it with your doctor first.
If you miss a dose of this medicine, take it as soon as you remember, unless it is almost time for your next dose. Do NOT double doses.
Talk with your doctor immediately if any of the following side effects occur: body produces substance that can bind to drug making it less effective or cause side effects; cough; difficulty swallowing; dizziness; fast heartbeat; hives; itching; puffiness or swelling of the eyelids or around the eyes, face, lips or tongue; shortness of breath; skin rash; tightness in chest; unusual tiredness or weakness; wheezing; abdominal fullness; blurred vision; changes in behavior; chest pain; confusion; difficult or labored breathing; faintness, or lightheadedness when getting up from a lying or sitting position suddenly; feeling unusually cold; feeling of warmth; fever; gaseous abdominal pain; nausea; redness of the face, neck, arms and occasionally, upper chest; shivering; sneezing; sore throat; sweating; thoughts of killing oneself; troubled breathing; or yellow eyes or skin.
TYSABRI (natalizumab) is a recombinant humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. The molecular weight of natalizumab is 149 kilodaltons. TYSABRI is supplied as a sterile, colorless, and clear to slightly opalescent concentrate for intravenous (IV) infusion. Each 15 mL dose contains 300 mg natalizumab; 123 mg sodium chloride, USP; 17.0 mg sodium phosphate, monobasic, monohydrate, USP; 7.24 mg sodium phosphate, dibasic, heptahydrate, USP; 3.0 mg polysorbate 80, USP/NF, in water for injection, USP at pH 6.1.
Generic name: Natalizumab
Similar drugs: Provigil ::